MMV receives funding and support from government agencies, private foundations, international organizations, corporate foundations and private individuals. These funds are used to finance MMV’s portfolio of research and development (R&D) projects to develop new, effective and affordable medicines for the treatment and prevention of malaria. They also support specific, targeted access and product management (APM) interventions to help ensure that vulnerable populations in malaria-endemic countries can access new malaria medicines.
Management estimates that MMV’s current portfolio will require an investment of approximately USD 100 million per annum over the 5-year period 2019–2023. With approximately USD 350 million available at the end of 2018 (USD 57 million cash as of 1 January 2019, USD 265 million committed pledges over the period 2019–2023 and the above-mentioned USD 28.4 million receivable from pharmaceutical partner GSK), the organization is currently tracking a shortfall of approximately USD 150 million up to the end of 2023.
Total donations received/pledged 1999-2024
MMV expenditure 2018: USD 84.5 million
MMV income and expenditure to date scenario 2019-2023
More details are available in the Financial Section of our Annual Report.